[Comment] A roadmap for accelerated drug approval in breast cancer?
01:16 EDT 9 Aug 2012 | The Lancet
Although much progress has been made in the development of targeted therapies in HER2-positive breast cancer over the past few years, trastuzumab is the only approved anti-HER2 drug in the adjuvant setting. In the largest neoadjuvant clinical trial a..
Original Article: [Comment] A roadmap for accelerated drug approval in breast cancer?
More From BioPortfolio on "[Comment] A roadmap for accelerated drug approval in breast cancer?"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
